The development of targeted therapies for prostate cancer reflects the central role of the androgen receptor (AR) signaling pathway, along with the recognition of molecular vulnerabilities such as DNA repair deficiencies and prostate-specific antigens. The gene discussed is AR; the disease is prostate cancer.